[CAS NO. 78123-71-4] DAMGO
PRODUCTS SPECIFICATIONS [78123-71-4]
DESCRIPTION [78123-71-4]
Overview
| MDL | MFCD00076432 |
|---|---|
| Molecular Weight | 513.59 |
| Molecular Formula | C26H35N5O6 |
| SMILES | - |
2 Publications Citing Use of MCE
Summary
DAMGO is a μ-opioid receptor ( μ-OPR ) selective agonist with a K d of 3.46 nM for native μ-OPR [1] .
IC50 & Target
Kd: 3.46±0.84 nM (native μ-OPR) [1]
In Vitro
DAMGO (1-10 μM) significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival, but does not down-regulate CXCR4 protein expression
[2]
.
DAMGO (1 μM) effectively inhibits the prostaglandin E 2 (PGE 2) induced increase in a tetrodotoxin-resistant voltage-gated Na
+
current (TTX-R I
Na
), i.e. PGE 2 (1 μM) can increase the TTX-R I
Na
peak by 103 % compared to 24.9 % with the addition of DAMGO
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
DAMGO (i.v., 0.5-2 mg/kg) can produce significant anti-injury effects on injured paws of male Sprague-Dawley rats weighing 200-225 g in a dose-dependent manner, producing an effective and long-lasting analgesic effect
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Sealed storage, away from moisture and light
| Powder | -80°C | 2 years |
|---|---|---|
| -20°C | 1 year |
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
H 2 O : ≥ 100 mg/mL ( 194.71 mM )
DMSO : 33.33 mg/mL ( 64.90 mM ; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.9471 mL | 9.7354 mL | 19.4708 mL |
| 5 mM | 0.3894 mL | 1.9471 mL | 3.8942 mL |
| 10 mM | 0.1947 mL | 0.9735 mL | 1.9471 mL |
References
- [1] FEBS Lett. 1995 Jan 2;357(1):93-7. Onogi T, et al. DAMGO, a mu-opioid receptor selective agonist, distinguishes between mu- and delta-opioid receptors around their first extracellular loops.
- [2] Patel JP, et al. Modulation of neuronal CXCR4 by the micro-opioid agonist DAMGO. J Neurovirol. 2006 Dec;12(6):492-500.
- [3] Gold MS, et al. DAMGO inhibits prostaglandin E2-induced potentiation of a TTX-resistant Na+ current in rat sensory neurons in vitro. Neurosci Lett. 1996 Jul 12;212(2):83-6.
- [4] Desmeules JA, et al. Selective opioid receptor agonists modulate mechanical allodynia in an animal model of neuropathic pain. Pain. 1993 Jun;53(3):277-285.